SBFM vs. TAOX, AKTX, RNTX, IMA, SONN, CVKD, LNAI, DARE, PASG, and ENLV
Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Synaptogenix (TAOX), Akari Therapeutics (AKTX), Rein Therapeutics (RNTX), ImageneBio (IMA), Sonnet BioTherapeutics (SONN), Cadrenal Therapeutics (CVKD), Lunai Bioworks (LNAI), Dare Bioscience (DARE), Passage Bio (PASG), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry.
Sunshine Biopharma vs. Its Competitors
Sunshine Biopharma (NASDAQ:SBFM) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.
Synaptogenix has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.35%. Sunshine Biopharma's return on equity of -26.04% beat Synaptogenix's return on equity.
In the previous week, Sunshine Biopharma had 2 more articles in the media than Synaptogenix. MarketBeat recorded 4 mentions for Sunshine Biopharma and 2 mentions for Synaptogenix. Sunshine Biopharma's average media sentiment score of 0.16 beat Synaptogenix's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.
Sunshine Biopharma has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
Sunshine Biopharma presently has a consensus price target of $7.00, indicating a potential upside of 234.93%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Synaptogenix.
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 0.1% of Sunshine Biopharma shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Sunshine Biopharma has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Sunshine Biopharma beats Synaptogenix on 11 of the 16 factors compared between the two stocks.
Get Sunshine Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sunshine Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:SBFM) was last updated on 10/18/2025 by MarketBeat.com Staff
